Business Wire

EXASOL

24.9.2020 10:17:10 CEST | Business Wire | Press release

Share
Exasol dominates its peer groups in BARC Data Management Survey 2020

Exasol , the high-performance analytics database, achieved 18 top-rankings and 4 leading positions in its two peer groups in The Data Management Survey 20. In addition, 100 percent of Exasol users chose the Exasol database because of its convincing performance and would recommend it to others. The survey was conducted by BARC (Business Application Research Center), Europe’s leading analyst firms for business software based in Würzburg, Germany.

“Exasol achieved truly remarkable results in the Data Management Survey 2020 with 18 top rankings,” said Timm Grosser, Senior Analyst Data & Analytics at BARC and author of the study. “Users gave Exasol the highest possible score for two crucial criteria when it comes to data platforms: 'performance' and 'platform reliability'. In today’s world, users need reliable and fast data for their operational and analytical processes. Similarly, the stability and performance of a data platform, even under pressure and high demand, are business-critical. Exasol has ranked impressively well in all the key areas and 100 percent of users surveyed in the Data Management Survey would recommend its high-performance analytics database to others.”

In the survey, twelve products were grouped into six peer groups to make them more comparable. The Exasol database was evaluated in both the Analytical Database Products peer group and the Data Warehouse Technologies peer group using twelve KPIs determined by BARC research. In both peer groups, the Exasol database was ranked top in the following categories:

  • Time to market;
  • Innovation power;
  • Performance;
  • Platform reliability;
  • Support quality;
  • Breadth of supported use cases;
  • Product satisfaction;
  • Recommendation.

In the group of Analytical Database Products, Exasol also achieved the top positions for Price-to-value and Functionality.

Exasol was ranked as a leader—among the top 25 to 30 percent of the products in the group—in the Developer Efficiency category in both peer groups, and in the data warehouse technologies peer group in the Price-to-value and Functionality categories.

“We are proud of our top rankings in BARC’s The Data Management Survey 2020. These excellent results show the high satisfaction of our customers,” said Aaron Auld, CEO of Exasol. “The fact that we scored ten out of ten in each of the two peer groups in the categories for Recommendation, Platform Reliability and Performance proves that we not only have the most powerful database for analytical workloads, but that we are committed to ensuring that our platform enables our customers to make data-driven decisions based on the most up-to-date data every day.”

The survey also shows that 93 percent of Exasol users use the database for data warehousing and business intelligence (BI) and 69 percent for data integration. Download the report, which includes a detailed overview of Exasol’s highlight results in BARC’S The Data Management Survey 2020.

###

About The Data Management Survey
The Data Management Survey 20 was conducted by BARC from December 2019 to March 2020. Altogether, 634 respondents worldwide answered a series of questions about their data management software. The survey offers a comparison of 12 leading data management tools across 12 criteria (KPIs) including developer efficiency, recommendation, time to market and product satisfaction. For more information, go to www.bi-survey.com.“

About Exasol
The Exasol high-performance analytics database is built to run faster than any other database, delivering next-level performance, scale and ease of use. Analyze billions of rows in seconds; run high-performance analytics securely in the cloud or on-premise; deliver frictionless analytics with self-indexing that automatically tunes performance; and scale out analytics for one transparent price. To learn more, please visit: www.exasol.com

###

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye